EFM
CLDX icon

E Fund Management’s Celldex Therapeutics CLDX Stock Holding History

E Fund Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Sell
7,918
-260
-3% -$8.4K 0.01% 382
2026
Q1 		$259K Buy
+8,178
New +$223K 0.01% 412
2025
Q2 		– Sell
-10,125
Closed -$184K – 409
2025
Q1 		$184K Sell
10,125
-660
-6% -$14.7K 0.01% 367
2024
Q4 		$273K Buy
+10,785
New +$293K 0.01% 331
2024
Q3 		– Sell
-7,258
Closed -$269K – 358
2024
Q2 		$269K Sell
7,258
-1,788
-20% -$67.5K 0.01% 248
2024
Q1 		$380K Buy
9,046
+1,097
+14% +$45K 0.02% 234
2023
Q4 		$315K Sell
7,949
-516
-6% -$15.2K 0.02% 225
2023
Q3 		$233K Sell
8,465
-2,587
-23% -$81.1K 0.02% 232
2023
Q2 		$375K Buy
11,052
+2,781
+34% +$93.7K 0.03% 185
2023
Q1 		$298K Buy
8,271
+760
+10% +$32.8K 0.02% 225
2022
Q4 		$335K Sell
7,511
-6,767
-47% -$242K 0.03% 212
2022
Q3 		$401K Buy
14,278
+78
+0.5% +$2.39K 0.04% 183
2022
Q2 		$383K Buy
14,200
+6,362
+81% +$185K 0.03% 197
2022
Q1 		$267K Buy
+7,838
New +$251K 0.01% 240

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

E Fund Management's CLDX Position: Q2 2026 in Review

E Fund Management reduced its Celldex Therapeutics (CLDX) stake by 3.2% in Q2 2026, selling an estimated $8.4K and leaving 7,918 shares worth $295K. The position accounts for 0.01% of the portfolio, ranked #382.

E Fund Management first reported a position in CLDX in Q1 2022 and has held it in 14 quarters since. The position peaked at $401K in Q3 2022. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • E Fund Management held 7,918 shares of Celldex Therapeutics worth $295K as of Q2 2026.
  • E Fund Management sold 260 Celldex Therapeutics shares in Q2 2026, an estimated $8.4K.
  • Celldex Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #382 holding.
  • E Fund Management first reported a position in Celldex Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • E Fund Management's Celldex Therapeutics position peaked at $401K in Q3 2022.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.